Application Note: Human primary cells and cytotoxicity testing for drug discovery
27 September 2021

The drug discovery workflow is heterogeneous, and the return on investment from this time-consuming process can be extremely low. While many factors affect the success of a drug-like molecule in the pipeline, positive cardiotoxicity tests are responsible for more than 80% of new drug recalls. Download this white paper by PromoCell to find out how you can use cytotoxicity testing in your drug discovery process to prevent setbacks in your research.